18:31Oui, nous sommes déjà en discussion avec des dizaines d'international biopharmes.
18:39Et le but est vraiment de créer une partnership pour travailler sur leurs candidats current
18:45et travailler side-by-side pour prouver que les insights que nous générons à Oracle
18:50sont très différents de ce qu'ils ont utilisé jusqu'à ce qui est either biologie-only
18:55dans le pré-clinical stage ou data-only dans le développement de clinique.
19:01Et ce que nous avons offert est un unique combination de both
19:04pour arbitrer des décisions all along le process.
19:07Et aujourd'hui, nous nous concentrons avec notre biopharma partenaire sur les questions de clinique.
19:13Est-ce que vous avez déjà des points d'actualité d'exploitation à l'audience ?
19:24Like giving maybe a couple of actually concrete examples
19:28so we understand exactly how this is working and the type of output you can have.
19:33Yeah.
19:34So let's say, for example, I mean, I can take or make up an example from two examples, but let's
19:43say...
19:43Don't say anything too confidential.
19:46We are recording.
19:46But let's say...
19:47Let's say...
19:50A biopharma has...
19:54It's the type of question there.
19:56It's like very tricky.
19:58So there's a huge competition in the Keras inhibitor, which has been the very famous and draggable target.
20:06And that finally, probably each one of the top pharma now has not one, but several Keras inhibitor all at
20:13the same time.
20:14So there's more than 50 Keras inhibitor at playing clinical trial today.
20:18Each pharma is very concerned about making the right decision on which molecule they're going to push,
20:24how it's performing as compared to the competition.
20:27So you have the companies may have several ones, like launching a phase two or phase three clinical trial can
20:35cost several hundred million euros.
20:38And it's going to take two to three years.
20:40So they want to know which one of the assets they're going to push and make sure they make the
20:44right decision.
20:44Just to give you an example.
20:46So that's the kind of partnership we're discussing.
20:51Thank you.
20:53I guess we're slowly coming to the end of the session.
20:56So maybe more as a closing remarks type of question.
21:04We see where we are now.
21:06We see at what pace this is progressing.
21:11Technology, the whole ecosystem of companies.
21:14We see like more tech bios every day popping up everywhere.
21:19We really see this type of velocity.
21:22It's kind of easy to understand where we are going in, let's say, two years.
21:28But it would be interesting maybe to discuss where you think we're going in 10 to 15 years.
21:34Taking into account the direction we already are taking.
21:39The technology that is involving.
21:40And yeah, what you see from this ecosystem.
21:45Sure.
21:46So maybe to start with what we know at Oracle.
21:51So with today's capabilities of the predictive engine, we expect to be able to switch from 5% of success
22:01rate to 25% of success rate, the ability to bring a drug to the patient, which will develop the
22:07therapeutic arsenal by fivefold, which is already a huge accomplishment.
22:12And I mean, I think like it's not only Oracle, but there's many companies here in Europe, but also in
22:18the U.S. who are working in that direction.
22:20So we know for sure we will be able to develop this therapeutic arsenal.
22:24What does that mean?
22:26That means that we finally will have many more drugs to treat cancer patients and deliver the promise of personalized
22:34treatments, which is not really true today.
22:36So by developing this therapeutic arsenal, making it to 1,000 drugs with the ability to do combination therapy, we
22:44will really be able to give the right drug or the right combination to the right patient at the right
22:49time and be able to custom the treatment for each patient.
22:53And so where does that take us?
22:55Maybe in more 20 or 30 years is that...
22:59Let's say 10.
23:00We don't have time.
23:02But like the goal is to make cancer a chronic disease like any other one, like diabetes or some inflammatory
23:11disease, because we will have like drugs for each stage of the disease.
23:18And we can make sure that we can actually keep this patient in great shape for decades like we do
23:26for any other disease.
23:29Thank you.
23:31We still have 33 seconds.
23:36I guess this is very exciting.
23:38Like this idea that cancer could just become another chronic disease in the next 15 to 20 years would be
23:43an amazing news for humanity, I would say.
23:48And maybe my conclusion would be that if this is happening and if your predictions are correct, it would be
23:55a good news for singular financial performance.
23:58Thank you, Fanny.
23:59Thank you, everyone.
24:00Thank you, Fanny.
24:00Thank you.
24:01Thank you.
24:02Thank you.
24:03Sous-titrage FR ?
Commentaires